Member Info for TWatcher

"Geez, Twatter, disingenuous sole aren't ya. you would have us believe that the success of Omega pivot around HMG"

I said "their covid Antigen play", and gave an exact quote from Colin King in the RNS which said exactly that. You said "Success of Omega".

Who is being disingenous ?

That minus figure in April for Innova in the above posting isn't a mistake, looks like they paid back £181M, but of course got another big wad in May.

Over a series of payments during May, Surescreen received a total of £23.6M. So about 8% value compared to Innova for May.

I wonder what Surescreens monthly capacity is ? Either they are only getting small orders compared to Innova, or they have a comparatively very small monthly capacity. It raises the question that when ODX & GAD start output, is the combined ODX/GAD/Surescreen output enough to make Innova redundant, if not then uk gov simply can not afford to remove their authorisation, even if the test isn't what they would like.

Also, the Innova test is still the same, very uncomfortable one to administer. A requirement of the DPS was that the test had to be the less invasive type. The Innova supply predates the DPS, so I wonder does that play into things too.

Also, given that in the results ODX clearly indicated that the companies they are talking with all have home use approval, I can not see that including Innova, as many people unsupervised, simply will not go right to the far end of the nose/mouth, making the test unsuitable for home settings.

So it still remains a very critical unknown, ODX said that all the companies they have engaged with are mass producing and have home test approval already....who are they ?

they made it clear in the RNS that the success of their covid antigen play is depends on the uk gov contract. EU and USA will be good icing on the cake, but there is no cake without gov contract.

"COVID-19 antigen testing still remains a significant opportunity for us, although very much dependent on the UK Government's decisions as to test selection and timing."

"I think there are only about 5 tests on that have been granted EUA"

https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2

There are 14 lateral flow antigen visual read tests that have been granted EUA authority in the US by the FDA. Of those 14, 8 are approved for home use/over the counter use.

Mologic has applied for Professional use EUA, not home/OTC use.

There is no list of how many applications are currently being processed by the FDA for EUA approval, nor do they give an indication of the process time.

$13.50 as I stated. Will be reiterated in the presentation Q&A at my request.

Finncap re-iterates today that 1M food detective tests in a couple of years times will generate £12M revenue.

it's a fact :)

Finncap re-iterates today that 1M food detective tests in a couple of years times will generate £12M revenue. Don't let people try to mask that by turning the thread into some sort of food fight.

Not once did I abuse you, my posting history is there for all to see.

You on the other hand do it virtually daily...which is all there to see.

If you don't like the numbers from the house broker, take it up with them.
Hey, Nice bit of name calling and abuse, which is you default position when you are wrong.

Bigjock36 April 2021
"This is the last ever post I will be placing on this board. The abuse I have received for trying to help shareholders was beyond any level I am comfortable receiving"

What a customer / distributor sells it for has zero impact on the ODX financials. Its what ODX gets for it that matters.

But you guys that insist that 1M test means revenue of $30M need to get onto Finncap, the house broker. Apparently no one told them, as in todays analysis of the results they say:-

"We have argued to the past that annual revenues could rise to £6-12M (0.5-1.0m tests) in the next couple of years which would generate gross profit of £4.0-£8.0M

1M test, £12M revenue. The same ratio as the 108K tests and £1.23M revenue stated in the results.

The extent that rampers are willing to run with any false narrative to try to suck people in, is shameful.

never let the facts get in the way of tramping down a user who actually is making sense, but not the sense you want to hear.

from todays presentation by the CFO at exactly 9 mins.
"In the years that's ended our chinese partner order over 100,00 tests, generating £1.23M pounds"

from the results today:-
"During the year they procured a further 108,126 tests" So the exact number of tests was 108,126.

Works out at £11.37. or around $15.35 using a $1.35 conversion rate.

All CK told us today is that by calendar 2023 (which is when the 1M units is being forecast), they are expecting the price to have softened a little to $13.50. either that or he misspoke and meant to says $15.50. Anyone that thinks the outlook since oct 2020 changed to effectively double the income , and they decided just not to mention that in either the forward looking statements or the outlook section of the full year results, should stick to crypto.

https://www.investormeetcompany.com/investor/meeting/trading-update-investor-presentation-1

Presentation in oct 202 time 39:20 "just as a reminder its $15.50 per test"

who the hell says "30 and a half dollars". listen, believe as you like, but its $13.50 dollars, down from $15.50. As if the selling price would double from last year and he wouldn't even mention it. Amazing what some in their own reality bubble are willing to believe.

18 mins in,
"selling price is in the region of 13 and a half dollars". Was $15 dollars a year ago.

That $30M is rubbish, he didn't say $30 a test, i'm pretty sure I heard $13.5 a test, which is more in keeping with the price he stated in the oct 2020 presentation which was stated as $15.5 a test with 70% markup. The oct 2020 presentation is online. check around 39 mins.

Its interesting, MHRA won't give approval for self-test if there is no demand from DHSC. Uk GOV put in the rtc contract that the contract could be cancelled if MHRA home approval didn't occur before a set date. So UK gov had all the cards in their pocket, it was IMPOSSIBLE to get MHRA approval, if DHSC (i.e. uk gov) decided it wasn't needed.

Can't think about conclusion until the gov tells them what test to make.

Avacta isn't being mass producced at this time.

"Already manufacturered at scale at the moment".."not just discussinng with one company".

There is only 1 UK company mass producing antigen LFT, Surescreen. Suggests that they are discussing with non uk company/s too. Wasn't it supposed to be a uk designed and manufactured test ? They wouldn't be chatting to Innova, would they ?